Tourette syndrome and other chronic tic disorders: an update on clinical management

References

• Ganos C, Martino D. Tics and Tourette syndrome. Neurol Clin. 2015;33:115–136.
   PubMed Web of Science ®Google Scholar
• Banaschewski T, Woerner W, Rothenberger A. Premonitory sensory phenomena and suppressibility of tics in Tourette syndrome: developmental aspects in children and adolescents. Dev Med Child Neurol. 2003;45:700–703.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
   Google Scholar
• Robertson MM. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. Lancet Psychiatry. 2015;2:68–87.
   PubMed Web of Science ®Google Scholar
• Groth C, Mol Debes N, Rask CU, et al. Course of Tourette syndrome and comorbidities in a large prospective clinical study. J Am Acad Child Adolesc Psychiatry. 2017;56:304–312.
   PubMed Web of Science ®Google Scholar
• Martino D, Pringsheim TM, Cavanna AE, et al. Systematic review of severity scales and screening instruments for tics: critique and recommendations. Mov Disord. 2017;32:467–473.
   PubMed Web of Science ®Google Scholar
• Leckman JF, Riddle MA, Hardin MT, et al. The Yale global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28:566–573.
   PubMed Web of Science ®Google Scholar
• Shapiro AK, Shapiro ES, Young JG. Measurement in tic disorders. Shapiro AK, Shapiro ES, Young JG, et al. editors. Gilles de la Tourette syndrome. 2nd ed. New York:Raven Press; 1988. p.451–480.
   Google Scholar
• Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorders severity. In: Cohen DJ, Bruun RD, Leckman JF, editors. Tourette’s syndrome and Tic disorders: clinical understanding and treatment. New York: John Wiley & Sons; 1988.
   Google Scholar
• Shytle RD, Silver AA, Sheehan KH, et al. The Tourette’s Disorder Scale (TODS): development, reliability, and validity. Assessment. 2003;10:273–287.
   PubMed Web of Science ®Google Scholar
• Woods DW, Piacentini J, Himle MB, et al. Premonitory urge for tics scale (PUTS): initial psychometric results and examination of the premonitory urge phenomenon in youths with tic disorders. Dev Behav Pediatr. 2005;26:397–403.
   PubMed Web of Science ®Google Scholar
• Martino D, Ganos C, Pringsheim TM. Tourette syndrome and chronic Tic disorders: the clinical spectrum beyond Tics. Int Rev Neurobiol. 2017;134:1461–1490.
   PubMed Web of Science ®Google Scholar
• Sambrani T, Jakubovski E, Müller-Vahl KR. New insights into clinical characteristics of Gilles de la Tourette syndrome: findings in 1032 patients from a single German center. Front Neurosci. 2016;10:415.
   PubMed Web of Science ®Google Scholar
• Barnea M, Benaroya-Milshtein N, Gilboa-Sechtman E, et al. Subjective versus objective measures of tic severity in Tourette syndrome - The influence of environment. Psychiatry Res. 2016;242:204–209.
   PubMed Web of Science ®Google Scholar
• Israelashvili M, Bar-Gad I. Corticostriatal divergent function in determining the temporal and spatial properties of motor Tics. J Neurosci. 2015;35:16340–16351.
   PubMed Web of Science ®Google Scholar
• Godar SC, Bortolato M. What makes you tic? Translational approaches to study the role of stress and contextual triggers in Tourette syndrome. Neurosci Biobehav Rev. 2017;76:123–133.
   PubMed Web of Science ®Google Scholar
• Conelea CA, Ramanujam K, Walther MR, et al. Is there a relationship between tic frequency and physiological arousal? Examination in a sample of children with co-occurring Tic and anxiety disorders. Behav Modif. 2014;38:217–234.
   PubMed Web of Science ®Google Scholar
• Conelea CA, Woods DW. The influence of contextual factors on tic expression in Tourette’s syndrome: a review. J Psychosom Res. 2008;65:487–496.
   PubMed Web of Science ®Google Scholar
• Conelea CA, Walther MR, Freeman JB, et al. Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the pediatric OCD treatment study II. J Am Acad Child Adolesc Psychiatry. 2014;53:1308–1316.
   PubMed Web of Science ®Google Scholar
• Termine C, Luoni C, Fontolan S, et al. Impact of co-morbid attention-deficit and hyperactivity disorder on cognitive function in male children with Tourette syndrome: a controlled study. Psychiatry Res. 2016;243:263–267.
   PubMed Web of Science ®Google Scholar
• Cavanna AE, Pansaon Piedad JC. Clinical Rating Instruments in Tourette syndrome. In: Martino D, Leckman JF, editors. Tourette Syndrome. New York: Oxford University Press; 2013. p. 411–438.
   Google Scholar
• Ambrosini PJ. Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS). J Am Acad Child Adolesc Psychiatry. 2000;39:49–58.
   PubMed Web of Science ®Google Scholar
• Spitzer B, Gibbon RL, Janet M, et al. Structured clinical interview for DSM‐IV Axis I disorders—patient edition (SCID I/P, version 2.0). New York, NY: American Psychiatric Press; 1996.
   Google Scholar
• Ghosh D, Rajan PV, Das D, et al. Sleep disorders in children with Tourette syndrome. Pediatr Neurol. 2014;51:31–35.
   PubMed Web of Science ®Google Scholar
• Schaefer SM, Chow CA, Louis ED, et al. Tic exacerbation in adults with Tourette syndrome: a case series. Tremor Other Hyperkinet Mov (N Y). 2017;7:450.
   PubMedGoogle Scholar
• Robakis D. How much do we know about adult-onset primary Tics? Prevalence, epidemiology, and clinical features. Tremor Other Hyperkinet Mov (N Y). 2017;7:441.
   PubMedGoogle Scholar
• Demartini B, Ricciardi L, Parees I, et al. A positive diagnosis of functional (psychogenic) tics. Eur J Neurol. 2015;22:527–e36.
   PubMed Web of Science ®Google Scholar
• Lebowitz ER, Scahill L. Psychoeducational interventions: what every parent and family member needs to know. In: Martino D, Leckman JF, editors. Tourette Syndrome. New York: Oxford University Press; 2013. p. 487–502.
   Google Scholar
• Nussey C, Pistrang N, Murphy T. How does psychoeducation help? A review of the effects of providing information about Tourette syndrome and attention-deficit/hyperactivity disorder. Child Care Health Dev. 2013;39:617–627.
   PubMed Web of Science ®Google Scholar
• Goussé V, Czernecki V, Denis P, et al. Arch Psychiatr Nurs. 2016;30:109–113.
   PubMed Web of Science ®Google Scholar
• Malli MA, Forrester-Jones R, Murphy G. Stigma in youth with Tourette’s syndrome: a systematic review and synthesis. Eur Child Adolesc Psychiatry. 2016;25:127–139.
   PubMed Web of Science ®Google Scholar
• Eddy CM, Cavanna AE. On being your own worst enemy: an investigation of socially inappropriate symptoms in Tourette syndrome. J Psychiatr Res. 2013;47:1259–1263.
   PubMed Web of Science ®Google Scholar
• Hirschtritt ME, Darrow SM, Illmann C, et al. Social disinhibition is a heritable subphenotype of tics in Tourette syndrome. Neurology. 2016;87:497–504.
   PubMed Web of Science ®Google Scholar
• Cavanna AE, Schrag A, Morley D, et al. The Gilles de la Tourette syndrome- quality of life scale (GTS-QOL): development and validation. Neurology. 2008;71:1410–1416.
   PubMed Web of Science ®Google Scholar
• Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. Jama. 2010;303:1929–1937.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Peterson AL, Piacentini J, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69:795–803.
   PubMed Web of Science ®Google Scholar
• Sukhodolsky DG, Woods DW, Piacentini J, et al. Moderators and predictors of response to behavior therapy for tics in Tourette syndrome. Neurology. 2017;88:1029–1036.
   PubMed Web of Science ®Google Scholar
• Woods DW, Piacentini J, Chang S, et al. Managing Tourette syndrome - A behavioral intervention for children and adults therapist guide. New York: Oxford University Press; 2008.
   Google Scholar
• Deckersbach T, Rauch S, Buhlmann U, et al. Habit reversal versus supportive psychotherapy in Tourette’s disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther. 2006;44:1079–1090.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Deckersbach T, Coffey BJ, et al. Habit reversal versus supportive psychotherapy for Tourette’s disorder: a randomized controlled trial. Am J Psychiatry. 2003;160:1175–1177.
   PubMed Web of Science ®Google Scholar
• Verdellen CW, Keijsers GP, Cath DC, et al. Exposure with response prevention versus habit reversal in Tourettes’s syndrome: a controlled study. Behav Res Ther. 2004;42:501–511.
   PubMed Web of Science ®Google Scholar
• O’Connor K, Lavoie M, Blanchet P, et al. Evaluation of a cognitive psychophyiological model for management of tic disorders: an open trial. Br J Psychiatry. 2016;209:76–83.
   PubMed Web of Science ®Google Scholar
• Himle MB, Freitag M, Walther M, et al. A randomized pilot trial comparing videoconference versus face-to-face delivery of behavior therapy for childhood tic disorders. Behav Res Ther. 2012;50:565–570.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Safety. 2011;34:651–668.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Pediatrics and Child Health. 2011;16:581–589.
   PubMed Web of Science ®Google Scholar
• Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette’s syndrome. Am J Psychiatry. 1978;135:585–587.
   PubMed Web of Science ®Google Scholar
• Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1989;46:722–730.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. Am J Psychiatry. 1997;154:1057–1062.
   PubMed Web of Science ®Google Scholar
• Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;62:50–56.
   PubMed Web of Science ®Google Scholar
• Gilbert DL, Batterson J, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43:206–214.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:596–603.
   PubMed Web of Science ®Google Scholar
• Wu M, Xiao GH, Yao M, et al. Multicenter clinical study on the treatment of children’s tic disorder with Qufeng Zhidong Recipe. Chin J Integr Med. 2009;15:254–260.
   PubMed Web of Science ®Google Scholar
• Shapiro AK, Shapiro E. Controlled study of pimozide vs. placebo in Tourette’s syndrome. J Am Acad Child Psychiatry. 1984;23:161–173.
   PubMedGoogle Scholar
• Dion Y, Annable L, Sandor P, et al. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22:31–39.
   PubMed Web of Science ®Google Scholar
• Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130–1135.
   PubMed Web of Science ®Google Scholar
• Gorman D, Gardner D, Murphy A, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder or conduct disorder. Can J Psych. 2015;60:62–76.
   Google Scholar
• Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013;74:e772–80.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Kohegyi E, Zhao J, et al. Once-daily oral aripiprazole for treatment of tics in children and adolescents with tourette’s disorder: a randomized, double-blind, placebocontrolled trial. Neuropsychopharmacology. 2014;39:S378–9.
   Web of Science ®Google Scholar
• Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39:292–299.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhang Z-J, Han X-M, et al. A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial. J Child Psychol Psychiatry. 2016;57:74–83.
   PubMed Web of Science ®Google Scholar
• Du YS, Li HF, Vance A, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry. 2008;42:807–813.
   PubMed Web of Science ®Google Scholar
• Leckman JF, Hardin MT, Riddle MA, et al. Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1991;48:324–328.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Wilson RS, et al. Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol. 1987;21:307–310.
   PubMed Web of Science ®Google Scholar
• Tourette’s Syndrome Study G. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58:527–536.
   PubMed Web of Science ®Google Scholar
• Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067–1074.
   PubMed Web of Science ®Google Scholar
• Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin Neuropharmacol. 2002;25:325–332.
   PubMed Web of Science ®Google Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53:153–173.
   PubMed Web of Science ®Google Scholar
• Reid JL, Campbell BC, Hamilton CA. Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists. Hypertension. 1984;6:71–75.
   Web of Science ®Google Scholar
• Marras C, Andrews D, Sime E, et al. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56:605–610.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81:70–73.
   PubMed Web of Science ®Google Scholar
• Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology. 2001;56:599–604.
   PubMed Web of Science ®Google Scholar
• Nicolson R, Craven-Thuss B, Smith J, et al. A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette’s disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:640–646.
   PubMed Web of Science ®Google Scholar
• Awaad YSE. Double-blind controlled randomized study of the use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. J Neurol Sci. 2009;285:S137.
   PubMed Web of Science ®Google Scholar
• Smith-Hicks CL, Bridges DD, Paynter NP, et al. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord. 2007;22:1764–1770.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Panza KE, Yaffa A, et al. N-acetylcysteine in the treatment of pediatric Tourette syndrome: randomized, double-blind, placebo-controlled add-on trial. J Child Adolesc Psychopharmacol. 2016;26:327–334.
   PubMed Web of Science ®Google Scholar
• Gabbay V, Babb JS, Klein RG, et al. A double-blind, placebo controlled trial of omega-3 fatty acids in Tourette’s disorder. Pediatrics. 2012;129:e1493–e500.
   PubMed Web of Science ®Google Scholar
• Zhao L, Li AY, Lv H, et al. Traditional Chinese medicine Ningdong granule: the beneficial effects in Tourette’s disorder. J Int Med Res. 2010;38:169–175.
   PubMed Web of Science ®Google Scholar
• Wang S, Qi F, Li J, et al. Effects of Chinese herbal medicine Ningdong granule on regulating dopamine (DA)/serotonin (5-TH) and gamma-amino butyric acid (GABA) in patients with Tourette syndrome. Biosci. 2012;6:212–218.
   Web of Science ®Google Scholar
• Muller-Vahl KR, Prevedel H, Theloe K, et al. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology. 2003;28:384–388.
   PubMed Web of Science ®Google Scholar
• Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35:57–61.
   PubMed Web of Science ®Google Scholar
• Howson AL, Batth S, Ilivitsky V, et al. Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome. Eur Psychiatry. 2004;19:102–112.
   PubMed Web of Science ®Google Scholar
• Silver AA, Shytle RD, Philipp MK, et al. Transdermal nicotine and haloperidol in Tourette’s disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001;62:707–714.
   PubMed Web of Science ®Google Scholar
• Silver AA, Shytle RD, Sheehan KH, et al. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette’s disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:1103–1110.
   PubMed Web of Science ®Google Scholar
• Peterson BS, Zhang H, Anderson GM, et al. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol. 1998;18:324–331.
   PubMed Web of Science ®Google Scholar
• Lemmon ME, Grados M, Kline T, et al. Efficacy of glutamate modulators in tic suppression: a double-blind, randomized control trial of D-serine and Riluzole in Tourette syndrome. Pediatr Neurol. 2015;52:629–634.
   PubMed Web of Science ®Google Scholar
• Toren P, Weizman A, Ratner S, et al. Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:499–503.
   PubMed Web of Science ®Google Scholar
• Kurlan R, Crespi G, Coffey B, et al. A multicentre randomized placebo-controlled clinical trial of pramipexole for Tourette’s syndrome. Mov Disord. 2012;27:775–778.
   PubMed Web of Science ®Google Scholar
• Hoekstra PJ, Minderaa RB, Kallenberg CG. Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry. 2004;65:537–542.
   PubMed Web of Science ®Google Scholar
• Donegan S, Dixon P, Hemming K, et al. A systematic review of placebo-controlled trials of topiramate: how useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug? Epilepsia. 2015;56:1910–1920.
   PubMed Web of Science ®Google Scholar
• Dell’Orto VG, Belotti EA, Goeggel-Simonetti B, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014;77:958–964.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitao CB, Pinto LC, et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obesity Rev. 2011;12:e338–47.
   PubMed Web of Science ®Google Scholar
• Muller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003;64:459–465.
   PubMed Web of Science ®Google Scholar
• Schrock LE, Mink JW, Woods DW, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015;30:448–471.
   PubMed Web of Science ®Google Scholar
• Deeb W, Rossi PJ, Porta M, et al. The international deep brain stimulation registry and database for Gilles de la Tourette syndrome: how does it work? Front Neurosci. 2016;10:170.
   PubMed Web of Science ®Google Scholar
• Kefalopoulou Z, Zrinzo L, Jahanshahi M, et al. Bilateral globus pallidus stimulation for severe Tourette’s syndrome: a double-blind, randomised crossover trial. Lancet Neurol. 2015;14:595–605.
   PubMed Web of Science ®Google Scholar
• Welter ML, Houeto JL, Thobois S, et al. Anterior pallidal deep brain stimulation for Tourette’s syndrome: a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:610–619.
   PubMed Web of Science ®Google Scholar
• Ackermans L, Duits A, Van Der Linden C, et al. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain. 2011;134:832–844.
   PubMed Web of Science ®Google Scholar
• Okun MS, Foote KD, Wu SS, et al. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013;70:85–94.
   PubMed Web of Science ®Google Scholar
• Maciunas RJ, Maddux BN, Riley DE, et al. Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. J Neurosurg. 2007;107:1004–1014.
   PubMed Web of Science ®Google Scholar
• Smeets AY, Duits AA, Leentjens AF, et al. Thalamic deep brain stimulation for refractory Tourette syndrome: clinical evidence for increasing disbalance of therapeutic effects and side effects at long-term follow-up. Neuromodulation. 2017 Jan 19. doi: 10.1111/ner.12556. [E-pub ahead of print].
   PubMedGoogle Scholar
• Baldermann JC, Schuller T, Huys D, et al. Deep brain stimulation for Tourette syndrome: a systematic review and meta-analysis. Brain Stimul. 2016;9:296–304.
   PubMed Web of Science ®Google Scholar
• Hameed MQ, Dhamne SC, Gersner R, et al. Transcranial magnetic and direct current stimulation in children. Curr Neurol Neurosci Rep. 2017;17:11. DOI:10.1007/s11910-017-0719-0
   Web of Science ®Google Scholar
• Mantovani A, Lisanby SH, Pieraccini F, et al. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsesive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol. 2006;9:95–100.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Lim WS, Lim MH, et al. 1-Hz low frequency repetitive transcranial magnetic stimulation in children with Tourette’s syndrome. Neurosci Lett. 2011;492:1–4.
   PubMed Web of Science ®Google Scholar
• Bloch Y, Arad S, Levkovitz Y. Deep TMS add-on treatment for intractable Tourette syndrome: a feasibility study. World J Biol Psychiatry. 2016;17:557–561.
   PubMed Web of Science ®Google Scholar
• Wu SW, Maloney T, Gilbert DL, et al. Functional MRI-navigated repetitive transcranial magnetic stimulation over supplementary motor area in chronic tic disorders. Brain Stimul. 2014;7:212–218.
   PubMedGoogle Scholar
• Landeros-Weisenberger A, Mantovani A, Motlagh MG, et al. Randomized sham controlled double-blind trial of repetitive transcranial magnetic stimulation for adults with severe Tourette syndrome. Brain Stimul. 2015;8:574–581.
   PubMed Web of Science ®Google Scholar
• Mrakic-Sposta S, Marceglia S, Mameli F, et al. Transcranial direct current stimulation in two patients with Tourette syndrome. Mov Disord. 2008;23:2259–2261.
   PubMedGoogle Scholar
• Ricketts EJ, Goetz AR, Capriotti MR, et al. A randomized waitlist-controlled pilot trial of voice over Internet protocol-delivered behavior therapy for youth with chronic tic disorders. J Telemed Telecare. 2016;22:153–162.
   PubMed Web of Science ®Google Scholar
• Jakubovski E, Reichert C, Karch A, et al. The ONLINE-TICS study protocol: a randomized observer-blind clinical trial to demonstrate the efficacy and safety of Internet-delivered behavioral treatment for adults with chronic tic disorders. Front Psychiatry. 2016;7:119.
   PubMed Web of Science ®Google Scholar
• Conelea CA, Wellen BCM. Tic treatment goes tech: a review of TicHelper.com. Cogn Behav Pract. 2017;24:374–381.
   PubMed Web of Science ®Google Scholar
• Blount TH, Lockhart AL, Garcia RV, et al. Intensive outpatient comprehensive behavioral intervention for tic: a case series. World J Clin Cases. 2014;2:569–577.
   PubMedGoogle Scholar
• Kim ES. Valbenazine: first global approval. Drugs. 2017;77:1123–1129.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6:422.
   PubMed Web of Science ®Google Scholar
• Servello D, Sassi M, Gaeta M, et al. Tourette syndrome (TS) bears a higher rate of inflammatory complications at the implanted hardware in deep brain stimulation (DBS). Acta Neurochir. 2011;153:629–632.
   PubMed Web of Science ®Google Scholar
• Almeida L, Martinez-Ramirez D, Rossi PJ, et al. Chasing tics in the human brain: development of open, scheduled and closed loop responsive approaches to deep brain stimulation for Tourette syndrome. J Clin Neurol. 2015;11:122–131.
   PubMed Web of Science ®Google Scholar